Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 24:5:119-127.
doi: 10.5414/ALX02205E. eCollection 2021.

Anti-IgE: A treatment option in allergic rhinitis?

Oliver Pfaar  1 , Francesca Gehrt  1 , Hansen Li  1   2 , Stefan A Rudhart  1   2 , Alexander Nastev  1   2 , Boris A Stuck  1   2 , Stephan Hoch  1   2
Affiliations
Review

Anti-IgE: A treatment option in allergic rhinitis?

Oliver Pfaar et al. Allergol Select. .

Abstract

Background: Allergic rhinitis (AR) is the most common IgE-mediated allergic disease. Multiple clinical trials have demonstrated promising results on the AR treatment with biologics, in particular with the use of omalizumab - an anti-IgE antibody. Omalizumab has also been established in the routine management of allergic asthma and chronic idiopathic urticaria. However, currently there is no approved license for the use of biologics in AR in Germany.

Materials and methods: A systematic literature review has been completed including randomized controlled trials, meta-analyses, and reviews on the treatment of AR with omalizumab.

Results: The systematic review demonstrates strong evidence supporting the use of omalizumab in the treatment of AR with regard to symptom control, safety profile, and management of comorbidities.

Conclusion: Omalizumab is a good and safe option in the treatment of AR in terms of symptom control and the management of pre-existing comorbidities. Further clinical trials with other biologics in the management of AR are needed and are expected to follow soon.

Keywords: allergen immunotherapy; allergic rhinitis; anti-IgE; biologics; omalizumab.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Clinical trials of omalizumab in AR. SAR = seasonal allergic rhinitis; PAR = perennial allergic rhinitis.
See this image and copyright information in PMC

References

    1. Bousquet J Khaltaev N Cruz AA Denburg J Fokkens WJ Togias A Zuberbier T Baena-Cagnani CE Canonica GW van Weel C Agache I Aït-Khaled N Bachert C Blaiss MS Bonini S Boulet LP Bousquet PJ Camargos P Carlsen KH Chen Y Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008; 63: 8–160. - PubMed
    1. Langen U Schmitz R Steppuhn H [Prevalence of allergic diseases in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013; 56: 698–706. - PubMed
    1. Björkstén B Clayton T Ellwood P Stewart A Strachan D Phase III Study Group ISAAC Worldwide time trends for symptoms of rhinitis and conjunctivitis: Phase III of the International Study of Asthma and Allergies in Childhood. Pediatr Allergy Immunol. 2008; 19: 110–124. - PubMed
    1. Scadding GK Optimal management of allergic rhinitis. Arch Dis Child. 2015; 100: 576–582. - PMC - PubMed
    1. Pfaar O Angier E Muraro A Halken S Roberts G Algorithms in allergen immunotherapy in allergic rhinoconjunctivitis. Allergy. 2020; 75: 2411–2414. - PubMed

LinkOut - more resources